Fenofibrate should not be given to patients with severe hepatic impairment or significant liver disease, gallstones or gallbladder disorders, or hypoalbuminaemic states such as nephrotic syndrome. It should be used with caution in renal impairment.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
